CCN2 and pancreatic neoplasm: A CTGF-specific antibody FG-3019 (FibroGen Inc.)inhibits pancreatic tumor growth and metastasis in nude mice [34], and a phase II clinical trial using FG-3019 in patients with pancreas cancer has announced positive activity (http://www.fibrogen.com/press/release/pr_1401519665).